Get the Stockscreener App
18.10
0.84%
0.15
Pulse Biosciences Inc stock is traded at $18.10, with a volume of 181.03K.
It is up +0.84% in the last 24 hours and up +19.79% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
See More
Previous Close:
$17.95
Open:
$18.23
24h Volume:
181.03K
Relative Volume:
0.61
Market Cap:
$1.23B
Revenue:
$-9,000
Net Income/Loss:
$-68.03M
P/E Ratio:
-17.24
EPS:
-1.05
Net Cash Flow:
$-44.76M
1W Performance:
-5.78%
1M Performance:
+19.79%
6M Performance:
+19.31%
1Y Performance:
+1.86%
1-Day Range:
$17.95
$18.95
1-Week Range:
$17.46
$19.63
52-Week Range:
$12.56
$26.30
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
18.10 | 1.22B | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
501.18 | 176.65B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
171.49 | 49.56B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
84.27 | 40.50B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
259.05 | 37.63B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
42.88 | 36.02B | 28.43B | 1.16B | 1.26B | 1.4457 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Mizuho | Outperform |
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
Thyroid experts review 15–22 month data on Pulse nPulse ablation - Stock Titan
PLSE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pulse Biosciences (NASDAQ:PLSE) Stock Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Pulse Biosciences Highlights nPulse Cardiac Ablation Progress - TipRanks
Pulse Biosciences posts updated investor deck highlighting nPulse cardiac catheter and strengthened EP focus - TradingView
Pulse Biosciences (NASDAQ: PLSE) releases updated March 2026 investor deck - Stock Titan
Pulse Biosciences, Inc (PLSE) Stock Analysis: Is A 59% Upside Within Reach? - DirectorsTalk Interviews
Market Wrap: Does Pulse Biosciences Inc have strong fundamentalsWeekly Earnings Recap & Weekly Top Stock Performers List - baoquankhu1.vn
Understanding the Setup: (PLSE) and Scalable Risk - Stock Traders Daily
Pulse Biosciences (PLSE) clarifies disclosure on CCO Kevin Danahy’s resignation - Stock Titan
Pulse Biosciences Executive Sells 60,000 Shares - TradingView
Is Pulse Biosciences (PLSE) Pricing Make Sense After Recent Volatility And Cash Flow Forecasts? - Yahoo Finance
Pulse Biosciences (PLSE) Is Down 12.6% After Wider Losses And New Funding PlansHas The Bull Case Changed? - simplywall.st
PLSE Should I Buy - Intellectia AI
Pulse Biosciences chief commercial officer resigns effective immediately - Investing.com
Pulse Biosciences Announces Resignation of Chief Commercial Officer - TipRanks
Chief Commercial Officer exits Pulse Biosciences (PLSE) with no stated dispute - Stock Titan
US med-tech companies bullish about 2026 - bioworld.com
Is Pulse Biosciences (PLSE) Share Price Justified After Recent Volatility In Healthcare Sentiment - simplywall.st
Pulse Biosciences (PLSE) Price Target Increased by 27.66% to 30.60 - Nasdaq
Pulse Biosciences, Inc (PLSE) Stock Analysis: Exploring a 48.59% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
ETF Watch: Will Perfect Corp Equity Warrant face regulatory challenges2025 Stock Rankings & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Pulse Biosciences CCO Danahy sells $118k in PLSE stock By Investing.com - Investing.com Canada
Kevin Patrick Danahy Sells 5,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock - MarketBeat
Pulse Biosciences (PLSE) CCO exercises options and sells 5,000 shares - Stock Titan
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 20, 2026 - BioSpace
Aug EndMonth: Is Pulse Biosciences Inc benefiting from innovation trendsTrade Entry Summary & Smart Swing Trading Techniques - baoquankhu1.vn
Pulse Biosciences (NASDAQ:PLSE) Rating Increased to Hold at Wall Street Zen - MarketBeat
MSN Money - MSN
Pulse Biosciences (NASDAQ:PLSE) Shares Down 6.5%Here's Why - MarketBeat
Pulse Biosciences Inc (PLSE) Shares Gap Down to $22.02 on Feb 20 - GuruFocus
Oppenheimer raises Pulse Biosciences stock price target to $30 By Investing.com - Investing.com Canada
Pulse Biosciences slips despite Q4 beat after deal to sell shares - MSN
Pulse Biosciences stock slips despite Q4 beat (PLSE:NASDAQ) - Seeking Alpha
Pulse Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference - The AI Journal
Pulse Biosciences earnings in focus after clinical data surge - Investing.com Australia
Decoding Pulse Biosciences Inc (PLSE): A Strategic SWOT Insight - GuruFocus
Pulse Biosciences Q4 2025 Earnings Call Transcript - MarketBeat
Pulse Biosciences Inc (PLSE) Q4 2025 Earnings Call Highlights: I - GuruFocus
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results - BioSpace
Pulse Biosciences Q4 Earnings Call Highlights - MarketBeat
Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates - Bitget
Pulse Biosciences Shares Fall After Q4 Loss Widens as Clinical Spending Rises and Revenue Remains Limited - AlphaStreet News
Pulse Biosciences to offer securities worth $200 million - marketscreener.com
Pulse Biosciences To Offer Securities Worth $200 Million - TradingView
Pulse Biosciences Establishes New $60 Million ATM Program - TipRanks
Pulse Biosciences (NASDAQ:PLSE) Releases Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Earnings Flash (PLSE) Pulse Biosciences, Inc. Reports Q4 Revenue $264K, vs. FactSet Est of $150K - marketscreener.com
PLSE: Advanced pivotal clinical programs in AF ablation with rising losses and modest initial revenue - TradingView
Pulse Biosciences Launches $59.98 Million ATM Equity Program With TD Cowen - TradingView
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):